CAMBRIDGE COGNITION LIMITED

Their core work

Cambridge Cognition is a UK health technology SME that develops digital tools for measuring cognitive function, fatigue, sleep, and daily activity — primarily for use in clinical research settings. Their core value is translating hard-to-measure neurological and functional symptoms into quantifiable digital endpoints that can be captured remotely. In H2020, they contributed this measurement expertise to large-scale clinical research programs targeting neurodegenerative diseases and immune-mediated inflammatory disorders, as well as to the infrastructure supporting remote decentralized clinical trials. They sit at the intersection of cognitive science, digital health, and clinical trial methodology.

What they specialise in

How they've shifted over time

Both H2020 projects began in 2019, so the timeline is narrow and longitudinal shifts are limited. However, the keyword pattern tells a story: initial engagement centred on the infrastructure of remote clinical trials broadly (Trials@Home), while their direct research participation in IDEA-FAST reveals deeper specialisation in digital biomarkers for specific conditions — neurodegeneration and inflammatory disease. The trajectory suggests a move from general remote-trial capability toward condition-specific digital measurement science.

They appear to be moving toward condition-specific digital endpoint development, particularly for chronic neurological and inflammatory diseases — a growing area in regulatory science as agencies like EMA increasingly accept digital endpoints in trial submissions.

How they like to work

Cambridge Cognition joins consortia as a specialist contributor rather than a project leader — they have never coordinated an H2020 project. Despite only two projects, they connected with 82 unique partners across 19 countries, indicating they join large, multi-institutional research programs where their specific measurement tools serve as one component of a broader research infrastructure. This suggests they are comfortable operating in complex, multi-partner settings as a focused technology provider.

82 unique consortium partners across 19 countries from just two projects, reflecting involvement in large pan-European research consortia. Their network is EU-wide with no obvious geographic concentration beyond their UK base.

What sets them apart

As a commercial SME with validated, research-grade cognitive and functional assessment tools, Cambridge Cognition occupies a niche that academic groups typically cannot fill: they bring production-quality digital measurement products into clinical research settings, not just prototype instruments. For consortium builders, this means they can deliver tools already tested in clinical populations and potentially available for licensing or integration beyond the project lifetime.

Highlights from their portfolio

• IDEA-FAST
  Their primary funded participation (EUR 150,000), directly developing digital endpoints for fatigue, sleep, and daily activities across neurodegenerative and inflammatory conditions — a high-priority area for modern clinical trial design.
• Trials@Home
  Involvement as a third party in a Center of Excellence for remote decentralized trials signals recognition of their measurement capabilities in the shifting landscape of post-COVID clinical trial delivery.